The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:5
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [41] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [42] Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis
    Liu, Jiaye
    Mu, Chunyang
    Li, Kewei
    Luo, Han
    Liu, Yong
    Li, Zhihui
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2021, 66
  • [43] Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort
    Bonfiglio, Caterina
    Tatoli, Rossella
    Donghia, Rossella
    Guido, Davide
    Giannelli, Gianluigi
    ANTIOXIDANTS, 2024, 13 (11)
  • [44] Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis
    Zeng, Yunqing
    Cao, Ruyue
    Tao, Ziwen
    Gao, Yanjing
    LIPIDS IN HEALTH AND DISEASE, 2022, 21 (01)
  • [45] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [46] Assessing the efficacy of farnesoid X receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis Efficacy of Farnesoid X Receptor Agonists in Metabolic Dysfunction- associated Steatotic Liver Disease: Systematic Review and Meta-analysis
    Kumar, Jai
    Hasan, Misha
    Mohsin, Sana
    Alzaher, Mojtaba Hussain
    Nagar, Tripti
    Jamil, Adeena
    Ahmed, Ali
    Krishna, Vamsi Lavu
    Kumar, Sarwan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2025, 49 (02)
  • [47] A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis. '
    Li, Chao
    Wang, Ting
    Song, Jinbo
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)
  • [48] Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis
    Tuo, Shuyue
    Yeo, Yee Hui
    Chang, Rachel
    Wen, Zhang
    Ran, Qiuju
    Yang, Longbao
    Fan, Qing
    Kang, Junxiu
    Si, Jiaojiao
    Liu, Yi
    Shi, Haitao
    Li, Yong
    Yuan, Jia
    Liu, Na
    Dai, Shejiao
    Guo, Xiaoyan
    Wang, Jinhai
    Ji, Fanpu
    Tantai, Xinxing
    CLINICAL NUTRITION, 2024, 43 (01) : 84 - 94
  • [49] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [50] Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
    Zhang, Yi
    Zhou, Ben-Gang
    Zhan, Ji-Dong
    Du, Bin-Bin
    FRONTIERS IN ONCOLOGY, 2024, 14